Letter regarding “Waiting for the changes after the adoption of steatotic liver disease”

Identification of signature gene set as highly accurate determination of metabolic dysfunction-associated steatotic liver disease progression

“…Metabolic dysfunction-associated steatotic liver disease (MASLD) is a metabolic disease characterized by fat accumulation in the liver [ 1 - 3 ]. MASLD includes simple steatosis, which is relatively early-stage and low risk, and metabolic dysfunction-associated steatohepatitis (MASH), which is late-stage disease characterized by serious liver inflammation and fibrosis [ 4 - 6 ].…”

Correspondence on Letter regarding “Waiting for the changes after the adoption of steatotic liver disease”

“…We have carefully reviewed the Letter to the editor by Yew et al and find their discussion on the implementation of the new nomenclature, steatotic liver disease (SLD), to be highly insightful [ 1 , 2 ]. Yew et al [ 2 ] raised crucial issues, with a particular emphasis on the insufficient consideration of differences between Western and Asian countries regarding the new definition of SLD.…”

“…We have carefully reviewed the Letter to the editor by Yew et al and find their discussion on the implementation of the new nomenclature, steatotic liver disease (SLD), to be highly insightful [ 1 , 2 ]. Yew et al [ 2 ] raised crucial issues, with a particular emphasis on the insufficient consideration of differences between Western and Asian countries regarding the new definition of SLD. Additionally, they highlighted the need for extensive discussions in the future regarding whether individuals with alcohol-related liver disease (ALD) should be included in the SLD category or another distinct disease framework.…”